CSGO-HBP-027 Pancreatic Cancer Clinical Trial Participant List

CSGO-HBP-027 trial data contains information on 200 patients with resectable pancreatic ductal adenocarcinoma (PDAC) enrolled in a Japanese multicenter, randomized phase II/III study. The dataset compares neoadjuvant chemotherapy with gemcitabine and S-1 (GS) against GS plus concurrent radiotherapy (GS-RT), with primary and secondary endpoints including overall survival and resection rates. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051250150) and authored by Yoshito Tomimaru.

Use Cases

• Compare overall survival rates between the GS and GS-RT treatment arms using stratified log-rank tests.
• Analyze R0 resection rate and histological tumor response as secondary endpoints across randomized patient groups.
• Evaluate progression-free survival and safety data from the two neoadjuvant therapy regimens.
• Assess patient allocation and outcomes based on the 1:1 randomization ratio to either GS or GS-RT.

Strengths

• Dataset originates from a registered, multicenter randomized phase II/III clinical trial (jRCTs051250150).
• Contains data on a defined cohort of 200 patients with resectable PDAC.
• Includes both primary (overall survival) and multiple secondary endpoints (resection rate, R0 rate, tumor response).

Limitations

• Small dataset scope at 9.5 KB, likely containing summary or metadata rather than detailed patient-level records.
• Specific column structure, row counts, and sample data are unavailable for review.
• Data is specific to a single trial in Japan, limiting generalizability to other populations or treatment protocols.

Provenance

Source

figshare, authored by Yoshito Tomimaru.

Collection Method

Data collected from the CSGO-HBP 027 multicenter, randomized clinical trial.

Time Range

Covers the trial enrollment and study period.

Freshness

Last updated March 2026, indicating planned future data.

Geography

Japan.